{
    "nctId": "NCT00810797",
    "briefTitle": "Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer",
    "officialTitle": "Intermittent Exemestane Therapy for Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic carcinoma of the breast\n* Hormone receptor (estrogen receptor \\[ER\\] and/or progesterone receptor \\[PR\\]) positive disease (defined as: ER and/or PR positivity as \\>= 5% staining), as confirmed by immunohistochemistry (IHC) based on primary breast tissue or metastatic tissue\n* Postmenopausal, as defined by any of the following:\n* Natural menopause, with at least 1 year since last menses\n* Chemotherapy-induced menopause with at least 1 year from last menses and serum luteinizing hormone (LH)/follicle-stimulating hormone (FSH) and estradiol levels within the postmenopausal range\n* History of surgical or radiation-induced ovarian ablation\n* For women =\\< 56 years old and with a history of hysterectomy but at least one ovary intact, serum LH/FSH and estradiol levels must be within the postmenopausal range\n* Postmenopausal women with disease recurrence while receiving either tamoxifen or a non-steroidal aromatase inhibitor (AI) as adjuvant therapy (as long as adjuvant hormonal therapy was taken for 6 months before disease progression) or with disease recurrence following the discontinuation/completion of adjuvant hormonal therapy\n* Postmenopausal women with disease progression following either 0, 1 or 2 prior hormonal therapies for metastatic breast cancer, as long as the subject has had no prior exposure to exemestane (EXE)\n* Measurable or non-measurable (but evaluable) disease, as defined by RECIST criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Neutrophil count \\>= 1.5 X 10\\^9 cells/L\n* Platelet count \\>= 100 X 10\\^9 cells/L\n* Serum creatinine =\\< 1.5 times upper limit of normal (ULN)\n* Total serum bilirubin =\\< 1.5 times ULN\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels =\\< 2.5 x ULN in patients without liver metastases or =\\< 5 times ULN in patients with liver metastases\n* Alkaline phosphatase =\\< 2.5 times the ULN for patients without bone or liver metastases\n* Subjects must have an estimated life expectancy of greater than 6 months\n\nExclusion Criteria:\n\n* Prior exposure to EXE, whether in the adjuvant or metastatic setting\n* Prior history of any other cancer with the exception of non-melanoma skin cancer and treated in situ carcinoma of the cervix\n* Active or symptomatic central nervous system (CNS) metastasis (stable or treated brain metastasis allowed but patients must be off decadron, if given for CNS disease)\n* Hormone-receptor negative or unknown breast cancer\n* More than two prior chemotherapy regimen for treatment of metastatic disease (any prior chemotherapy given in the adjuvant setting is permitted)\n* Administration of any other anti-cancer therapy within 2 weeks of initiating study treatment; use of bisphosphonates, however, are permitted for patients with known bone metastases\n* Treatment with any other concurrent investigational agent or anti-tumor drug (chemotherapy, antibody therapy or other biologic agents), will not be permitted\n* Subjects who have had no prior exposure to endocrine therapy\n* Any uncontrolled medical co-morbidity or psychiatric disorder which interferes with the ability to provide informed consent or comply with study procedures",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}